AOD-9604

Chronic Preclinical Studies

In murine models spanning 12–24 weeks, AOD-9604 administration produced sustained fat mass reductions without changes in lean body mass, bone metabolism markers, or endocrine axis engagement. Serum IGF-1 concentrations remained unchanged throughout treatment periods. Effects were preferential in obese fat depots versus lean adipose tissue.

Pooled Phase 1/2 Safety Analysis

A pooled analysis of six randomized, double-blind, placebo-controlled Phase 1/2 trials (>900 participants) demonstrated that AOD-9604 is exceptionally well tolerated:

• IGF-1 levels did not rise relative to placebo
• Oral glucose tolerance, insulin sensitivity, and carbohydrate metabolism parameters unchanged
• No anti-AOD-9604 antibodies detected
• Adverse events and withdrawals indistinguishable from placebo

This data supports the idea that AOD-9604 behaves like placebo with respect to major endocrine and glycemic safety signals.

Phase 2b Clinical Trial (OPTIONS)

A 24-week Phase 2b trial (~534 obese adults) evaluated multiple doses of oral AOD-9604. The fragment showed placebo-comparable safety profiles. Modest weight loss differences (~2% net difference) were observed compared to placebo, though results did not meet regulatory efficacy thresholds for obesity indication. Development as a stand-alone obesity therapy was discontinued.

Oral Bioavailability

Unlike most peptides that degrade in the gut, AOD-9604 demonstrates detectable bioavailability following oral administration — an unusual property that enabled oral dosing in clinical trials.

Cartilage Biology

Separate research has examined AOD-9604's effects on chondrocyte function and cartilage matrix dynamics in osteoarthritis models. These effects appear mechanistically independent from its adipocyte activity, suggesting biological properties beyond fat metabolism. Mechanisms remain poorly defined.

In 2019, AOD-9604 received Generally Recognized As Safe (GRAS) status from the FDA for use as a food ingredient — an unusual classification for a bioactive peptide. This reflects review of available toxicology data but does not constitute approval for therapeutic use.

Phase 2b trial results did not meet efficacy thresholds for obesity indication approval. The ~2% net weight loss difference is small compared to modern incretin-based therapies achieving 15–25%. While preclinical lipolytic effects are well-characterized through β-3 receptor pathways, translation to clinical weight loss endpoints has been modest. Most clinical data comes from oral administration studies; injectable pharmacokinetics may differ. AOD-9604 is best understood as a safety-strong but efficacy-modest fragment — potentially useful as a fine-tuning adjunct in optimized protocols rather than a primary intervention.

• Ng FM, et al. Structure-activity relationships of truncated forms of human growth hormone with fat cells. J Mol Endocrinol 2000.
• Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001.
• Thompson G, et al. Growth hormone fragment AOD9604: oral bioavailability and effects on obesity in rodents and humans. J Endocrinol 2004.
• Stier H, et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Invest 2013.

For laboratory research use only.